DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.

Author(s): Arumainathan A, Kalakonda N, Pettitt AR

Affiliation(s): Directorate of Clinical Haematology, Royal Liverpool & Broadgreen University Hospitals NHS Trust, Liverpool, UK.

Publication date & source: 2011-10, Eur J Haematol., 87(4):372-5. Epub 2011 Aug 11.

Publication type: Case Reports

Lenalidomide is an immunomodulatory agent with activity in a range of haematological cancers including chronic lymphocytic leukaemia (CLL). However, major questions remain concerning its effectiveness in patients with T-cell depletion or deletion of TP53 on chromosome 17p. This case report provides insight into these questions by showing that lenalidomide/dexamethasone in combination can be highly effective as induction therapy for refractory 17p-CLL, that remission quality can be improved by subsequent maintenance with lenalidomide alone and that the anti-leukaemic effects of lenalidomide and its stimulatory effects on non-malignant B cells are preserved despite prolonged T-cell depletion resulting from prior alemtuzumab/methylprednisolone. (c) 2011 John Wiley & Sons A/S.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017